A retrospective review of vaginal cancer outcomes at a tertiary referral centre in the UK
Jayshree Veeratterapillay,
United Kingdom
PO-2148
Abstract
A retrospective review of vaginal cancer outcomes at a tertiary referral centre in the UK
Authors: Jayshree Veeratterapillay1, Lorna Dodd2, Laa'li Guttierez1, Rahul Patil1, Sandeep Singhal1, David Morgan3
1Northern Centre for Cancer Care, Freeman Hospital, Clinical Oncology, Newcastle Upon Tyne, United Kingdom; 2Northern Centre for Cancer Care, Freeman Hospital, Clinical Oncology, Newcastle Upon Tyne Hospitals , United Kingdom; 3Northern Centre for Cancer Care, Freeman Hospital, Medical Physics , Newcastle Upon Tyne, United Kingdom
Show Affiliations
Hide Affiliations
Purpose or Objective
The aim of this retrospective review is to assess local outcomes following definitive radio(chemo)therapy +/- brachytherapy in patients with vaginal cancer treated at a tertiary referral centre.
Material and Methods
Patients with vaginal cancer who received radical intent treatment between October 2008- January 2022 were included. Retrospective data was collected from electronic records including patient demographics, tumour characteristics and treatment details. Kaplan Meier scores were used to estimate local control, progression free and overall survival.
Results
33 patients were included, with a median age of 66 years. 100% had squamous cell carcinoma. 52% of patients had FIGO stage 1/2 disease, 39% had FIGO 3/4a disease and staging was unknown in 9% of patients.
All patients received initial external beam radiotherapy (82% received 45Gy/25 fractions, 12% received 50Gy/25 fractions and 6% received other doses); 61% of patients received concurrent chemotherapy with cisplatin.
Following this, n=21 (64%) of patients were treated with brachytherapy (n=14 with intracavitary brachytherapy, n=7 with interstitial brachytherapy) and n=10 (30%) of patients received an external beam boost.
Median EQD2 doses (α/β ratio of 10) for patients treated with brachytherapy was 63Gy and with EBRT boost was 54.25Gy.
With a median follow up of 53 months, 3 and 5 year OS were 81 and 76.7% respectively. 3 and 5 year PFS were 78 and 78% respectively and 3 and 5 year local control were 81 and 76.3% respectively.
Conclusion
Vaginal cancer remains a rare disease with no prospective randomised trials to guide management. Data from our small cohort is comparable to international published outcomes. The RETRO EMBRAVE study showed further improved local control rates with T2-T4 tumours with EQD2 doses of >80 Gy to CTV using image guided adaptive brachytherapy. We currently use the MUPIT template for interstitial brachytherapy at our centre but are keen to review image guided adaptive brachytherapy techniques for suitable patients with vaginal cancer.